Last reviewed · How we verify

NCT03051035

First-in-Human Study of KO-947 in Non-Hematological Malignancies

Terminated Phase 1 Last updated 20 September 2021
What this trial tests

Phase 1 trial testing KO-947 in Advanced Malignant Neoplasm in 61 participants. Terminated before completion.

Timeline
6 April 2017
Primary endpoint
2 June 2020
2 June 2020

Quick facts

Lead sponsorKura Oncology, Inc.
PhasePhase 1
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment61
Start date6 April 2017
Primary completion2 June 2020
Estimated completion2 June 2020
Sites5 locations across United States, Spain

Drugs / interventions tested

Conditions studied

Sponsor

Kura Oncology, Inc. — full company profile →

Who can join

18 and older, any sex, with Advanced Malignant Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase 1 first-in-human (FIH) dose escalation study will determine the maximum tolerated dose (MTD) of KO-947 in subjects with locally advanced unresectable or metastatic, relapsed and/or refractory, non-hematological malignancies. If an MTD cannot be identified, a recommended phase 2 dose (RP2D) will be determined. In addition, two tumor specific extension cohorts may be conducted to further characterize the safety and tolerability of KO-947 and provide preliminary evidence of anti-tumor activity.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. RAS-targeted therapies: is the undruggable drugged?
    Moore AR, Rosenberg SC, McCormick F, Malek S. · · 2020 · cited 832× · PMID 32528145 · DOI 10.1038/s41573-020-0068-6
  2. The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy.
    Yuan J, Dong X, Yap J, Hu J. · · 2020 · cited 388× · PMID 32807225 · DOI 10.1186/s13045-020-00949-4
  3. Emerging strategies to target RAS signaling in human cancer therapy.
    Chen K, Zhang Y, Qian L, Wang P. · · 2021 · cited 164× · PMID 34301278 · DOI 10.1186/s13045-021-01127-w
  4. Development of small molecule extracellular signal-regulated kinases (ERKs) inhibitors for cancer therapy.
    Pan X, Pei J, Wang A, Shuai W, et al · · 2022 · cited 49× · PMID 35646548 · DOI 10.1016/j.apsb.2021.12.022
  5. KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup.
    Xie M, Xu X, Fan Y. · · 2021 · cited 46× · PMID 34012925 · DOI 10.3389/fonc.2021.672612
  6. Targeting ERK beyond the boundaries of the kinase active site in melanoma.
    Sammons RM, Ghose R, Tsai KY, Dalby KN. · · 2019 · cited 29× · PMID 31190430 · DOI 10.1002/mc.23047
  7. From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer.
    Bazzichetto C, Conciatori F, Luchini C, Simionato F, et al · · 2020 · cited 24× · PMID 32012917 · DOI 10.3390/cells9020309
  8. Targeting RAS mutants in malignancies: successes, failures, and reasons for hope.
    Yang H, Zhou X, Fu D, Le C, et al · · 2023 · cited 19× · PMID 36316602 · DOI 10.1002/cac2.12377

Verify or expand the search:

Other recruiting trials for Advanced Malignant Neoplasm

Currently open trials in the same condition.

Other Kura Oncology, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03051035.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing